ID-8

• CAT Number: I001806
• CAS Number: 147591-46-6
• Molecular Formula: C16H14N2O4
• Molecular Weight: 298.30
• Purity: ≥95%
• Synonyms: 1-(4-methoxyphenyl)-2-methyl-3-nitro-1H-indol-6-ol
• Target: DYRK
• Solubility: DMSO: ≥ 47 mg/mL
• Storage: -20°C
• IUPAC Name: 1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol
• InChI: InChI=1S/C16H14N2O4/c1-10-16(18(20)21)14-8-5-12(19)9-15(14)17(10)11-3-6-13(22-2)7-4-11/h3-9,19H,1-2H3
• InChIKey: VVZNWYXIOADGSW-UHFFFAOYSA-N
• SMILES: CC1=C(C2=C(N1C3=CC=C(C=C3)OC)C=C(C=C2)O)[N+](=O)[O-]

ID-8（Cat No.:I001806）is a small-molecule inhibitor of interleukin-8 (IL-8), a cytokine involved in inflammation, angiogenesis, and tumor progression. By blocking IL-8 signaling, ID-8 reduces pro-inflammatory and pro-angiogenic responses, making it valuable in cancer research and studies related to chronic inflammatory diseases. Its inhibitory effects on IL-8 help prevent the recruitment of neutrophils and the formation of new blood vessels that support tumor growth. ID-8’s ability to modulate immune responses makes it a promising tool for investigating targeted therapies in cancer, inflammation, and immune-mediated disorders.

Reference

1:Int J Oncol. 2001 Sep;19(3):599-607. Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant.Sylvain V,Lafarge S,Bignon YJ, PMID: 11494042
Abstract: BRCA1 germline mutations have been linked to the development of hereditary breast and ovarian cancers. Recent studies suggest that BRCA1 may function in the regulation of basic cellular processes, including gene transcription, and sensing and/or repair of DNA damage. To further delineate the BRCA1 upstream and downstream steps involved in its role in the cellular response to ionizing radiation, we compared the effects of expression of an exogenous full-length Brca1 with those of a truncated Brca1 mutant in the ID-8 mouse ovarian cancer cell line after irradiation. We found that expression of both full-length and truncated Brca1 increased resistance to ionizing radiation. Expression of truncated, but not full-length, Brca1 then allowed us to identify new potential downstream targets of mutated BRCA1 like MAPK/ERK pathway members and also key genes involved in mutated BRCA1 signaling pathway response to ionizing radiation such as p53 and p21WAF1/CIP1. We therefore established an in vitro mouse model for studying the molecular effects of human BRCA1 germline mutations.